PREVIEW
OF YOUR NEWS WIDGETCrohn^s disease news and crohn^s disease widget
Saturday, November 08, 2008 ( change date )
Abbott's HUMIRA® (adalimumab) Data Shows Fistula Healing For Up To Three Years In Patients With Moderate To Severe Crohn's Disease
New data showed that Abbott's (NYSE: ABT) HUMIRA® (adalimumab) provided long-term treatment of fistulas, with more than half of patients with moderate to severe Crohn's disease experiencing fistula healing at three years, according to clinical research presented today at the United European Gastroenterology Week (UEGW) congress in Vienna.
Medicalnewstoday.com Saturday, November 08, 2008
INSTALL YOUR WIDGET